Biomarkers in localized prostate cancer

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Prostate-specific antigen (PSA) is a widely used biomarker for prostate cancer, but its accuracy for early diagnosis is limited due to its organ-specific, not cancer-specific, nature.
• Existing models incorporating PSA with other markers like prostate cancer antigen 3 and kallikreins offer improvements but are not fully satisfactory.
• Emerging research in metabolomics, including preliminary data on sarcosine, suggests potential new avenues for biomarker discovery.

Purpose of the Study:

• To review the most relevant molecular biomarkers for the early diagnosis of localized prostate cancer.
• To discuss the limitations of current biomarkers like PSA and the potential of novel markers.
• To highlight advancements in genomics, proteomics, and metabolomics for identifying improved diagnostic and management tools.

Main Methods:

• Literature review of recent studies on prostate cancer biomarkers.
• Analysis of data on established biomarkers (PSA, PCA3, kallikreins, PSA isoforms).
• Exploration of emerging biomarker sources including metabolomics (sarcosine), genomics, and proteomics.

Main Results:

• Prostate-specific antigen (PSA) alone has suboptimal accuracy for prostate cancer diagnosis.
• Combined models using PSA with other biomarkers (e.g., PCA3, proPSA, intact PSA, kallikreins) enhance diagnostic performance.
• Metabolomic, genomic, and proteomic approaches are identifying novel molecular biomarkers with potential clinical utility.

Conclusions:

• Novel molecular biomarkers identified through advanced 'omics' technologies are crucial for improving prostate cancer early diagnosis and management.
• Integrating these new biomarkers into diagnostic models can overcome the limitations of PSA alone.
• Further research and validation are needed to translate these findings into clinical practice for localized prostate cancer.